D.A. Davidson & CO. Trims Stock Holdings in IQVIA Holdings Inc. $IQV

D.A. Davidson & CO. lowered its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 18.1% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 22,261 shares of the medical research company’s stock after selling 4,929 shares during the quarter. D.A. Davidson & CO.’s holdings in IQVIA were worth $3,796,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of IQV. Ameliora Wealth Management Ltd. acquired a new stake in shares of IQVIA during the fourth quarter worth about $25,000. International Assets Investment Management LLC acquired a new position in IQVIA in the 4th quarter worth approximately $27,000. Gilpin Wealth Management LLC purchased a new position in IQVIA during the 4th quarter worth approximately $27,000. CrossGen Wealth LLC acquired a new stake in IQVIA during the 4th quarter valued at approximately $28,000. Finally, Activest Wealth Management boosted its holdings in shares of IQVIA by 590.0% in the 4th quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 118 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have recently weighed in on IQV. Morgan Stanley reiterated an “equal weight” rating and issued a $200.00 price objective (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. Evercore reaffirmed an “outperform” rating and issued a $185.00 price target on shares of IQVIA in a report on Wednesday, April 8th. Weiss Ratings raised IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday. Robert W. Baird lifted their price objective on IQVIA from $230.00 to $249.00 and gave the company an “outperform” rating in a research note on Wednesday, July 1st. Finally, Wall Street Zen downgraded IQVIA from a “buy” rating to a “hold” rating in a research note on Saturday, June 27th. Fourteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $225.71.

IQVIA Price Performance

NYSE:IQV opened at $206.26 on Monday. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75. The company has a 50 day moving average price of $185.04 and a 200-day moving average price of $187.88. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $247.04. The firm has a market cap of $34.42 billion, a price-to-earnings ratio of 25.56, a price-to-earnings-growth ratio of 1.85 and a beta of 1.20.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The company had revenue of $4.15 billion during the quarter, compared to analysts’ expectations of $4.10 billion. During the same quarter in the previous year, the company earned $2.70 earnings per share. The firm’s revenue for the quarter was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Equities research analysts forecast that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA announced that its Board of Directors has approved a stock repurchase plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s management believes its shares are undervalued.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.